Initial drug regimens for the treatment of tuberculosis - Evaluation of physician prescribing practices in New Jersey, 1994 to 1995

被引:28
作者
Liu, ZY
Shilkret, KL
Finelli, L
机构
[1] New Jersey Dept Hlth & Senior Serv, Div Communicable Dis, Trenton, NJ 08625 USA
[2] Ctr Dis Control & Prevent, Atlanta, GA USA
关键词
initial drug regimen; physician practice; treatment; tuberculosis;
D O I
10.1378/chest.113.6.1446
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objective: To evaluate physician prescribing practices for the initial therapy for tuberculosis (TB) according to the recommendations of the Centers for Disease Control and Prevention (CDC) and American Thoracic Society (ATS). Design: Cross-sectional study. Setting: Statewide TB surveillance system in New Jersey, 1994 to 1995. Patients: We studied 1,230 culture-positive TB patients who were alive at diagnosis and whose isolates were tested for isoniazid susceptibility. Results: Almost all TB patients (98%) were reported from counties with an isoniazid-resistant proportion of 4% or more, which is the minimum level for implementation of an initial four-drug regimen recommended by CDC/ATS. Overall, 36% of the 1,230 patients were not initially treated with four or more drugs. Multivariate analyses found that non-Hispanic white patients were more likely to be treated with fewer than four drugs than were non-Hispanic black patients. Private practitioners and physicians at chest clinics were about five times more likely to prescribe fewer than four drugs initially than were physicians at the hospital where a national TB center is located. Conclusion: A substantial proportion of physicians did not initially treat their TB patients according to the CDC/ATS recommendations. The results suggest that New Jersey physicians should be better informed about the recommendation and the high level of drug resistance in the communities they serve to assure that TB patients receive appropriate initial therapy.
引用
收藏
页码:1446 / 1451
页数:6
相关论文
共 27 条
[1]  
ALLAN WGL, 1982, TUBERCLE, V63, P89
[2]  
[Anonymous], MMWR RECOMM REP
[3]   TREATMENT OF TUBERCULOSIS AND TUBERCULOSIS INFECTION IN ADULTS AND CHILDREN [J].
BASS, JB ;
FARER, LS ;
HOPEWELL, PC ;
OBRIEN, R ;
JACOBS, RF ;
RUBEN, F ;
SNIDER, DE ;
THORNTON, G .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 149 (05) :1359-1374
[4]   HOSPITAL OUTBREAK OF MULTIDRUG-RESISTANT MYCOBACTERIUM-TUBERCULOSIS INFECTIONS - FACTORS IN TRANSMISSION TO STAFF AND HIV-INFECTED PATIENTS [J].
BECKSAGUE, C ;
DOOLEY, SW ;
HUTTON, MD ;
OTTEN, J ;
BREEDEN, A ;
CRAWFORD, JT ;
PITCHENIK, AE ;
WOODLEY, C ;
CAUTHEN, G ;
JARVIS, WR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (10) :1280-1286
[5]   NATIONWIDE SURVEY OF DRUG-RESISTANT TUBERCULOSIS IN THE UNITED-STATES [J].
BLOCH, AB ;
CAUTHEN, GM ;
ONORATO, IM ;
DANSBURY, KG ;
KELLY, GD ;
DRIVER, CR ;
SNIDER, DE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (09) :665-671
[6]  
Bloch AB, 1996, PUBLIC HEALTH REP, V111, P26
[7]  
*CDC, 1990, MMWR-MORBID MORTAL W, V39, P39
[8]  
*CDCP, 1994, SURVS TB SOFTW EXP T
[9]  
[Anonymous], 1992, MMWR Recomm Rep, V41, P1
[10]  
Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1